CN1044116C - 用作il-1作用抑制剂的苯磺酰亚胺衍生物及其用途 - Google Patents
用作il-1作用抑制剂的苯磺酰亚胺衍生物及其用途 Download PDFInfo
- Publication number
- CN1044116C CN1044116C CN94194304A CN94194304A CN1044116C CN 1044116 C CN1044116 C CN 1044116C CN 94194304 A CN94194304 A CN 94194304A CN 94194304 A CN94194304 A CN 94194304A CN 1044116 C CN1044116 C CN 1044116C
- Authority
- CN
- China
- Prior art keywords
- compound
- chloro
- acid
- reaction
- milliliters
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15901493A | 1993-11-29 | 1993-11-29 | |
US159014 | 1993-11-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1136311A CN1136311A (zh) | 1996-11-20 |
CN1044116C true CN1044116C (zh) | 1999-07-14 |
Family
ID=22570705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN94194304A Expired - Fee Related CN1044116C (zh) | 1993-11-29 | 1994-11-03 | 用作il-1作用抑制剂的苯磺酰亚胺衍生物及其用途 |
Country Status (21)
Country | Link |
---|---|
US (1) | US5684017A (hu) |
EP (1) | EP0731791B1 (hu) |
JP (1) | JPH09506345A (hu) |
KR (1) | KR100340375B1 (hu) |
CN (1) | CN1044116C (hu) |
AT (1) | ATE177083T1 (hu) |
AU (1) | AU683114B2 (hu) |
CA (1) | CA2175458C (hu) |
DE (1) | DE69416859T2 (hu) |
DK (1) | DK0731791T3 (hu) |
ES (1) | ES2131297T3 (hu) |
FI (1) | FI109901B (hu) |
GR (1) | GR3029827T3 (hu) |
HU (1) | HU219565B (hu) |
IL (1) | IL111776A (hu) |
NO (1) | NO306211B1 (hu) |
NZ (1) | NZ276577A (hu) |
PT (1) | PT731791E (hu) |
TW (1) | TW279161B (hu) |
WO (1) | WO1995014669A1 (hu) |
ZA (1) | ZA949303B (hu) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6562629B1 (en) | 1999-08-11 | 2003-05-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum |
DE19705133A1 (de) * | 1997-02-11 | 1998-08-13 | Hoechst Ag | Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
KR20010024533A (ko) * | 1997-10-17 | 2001-03-26 | 오흘러 로스 제이. | 퀴놀린 유도체의 치료적 용도 |
DE19858253A1 (de) * | 1998-12-17 | 2000-06-21 | Aventis Pharma Gmbh | Verwendung von Inhibitoren des KQt1-Kanals zur Herstellung eines Medikaments zur Behandlung von Krankheiten, die durch Helminthen und Ektoparasiten hervorgerufen werden |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
EP1406621A2 (en) * | 2001-06-26 | 2004-04-14 | Beth Israel Deaconess Medical Center | Compositions and methods for inhibiting platelet activation and thrombosis |
EP2087908B1 (en) | 2001-06-26 | 2018-05-30 | Amgen Inc. | Antibodies to opgl |
WO2004060911A2 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
KR100687522B1 (ko) * | 2005-05-28 | 2007-02-27 | 한국화학연구원 | 2,2-디메틸-3-에스테르-4-알콕시-6-알킬 아미노벤조피란 유도체를 유효성분으로 함유하는 pge2 활성에 관련된 염증질환 치료제 |
CN104447489B (zh) * | 2014-12-29 | 2017-01-11 | 南京工业大学 | 3,4-二芳基马来酰亚胺衍生物及其制备方法与应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992015565A1 (en) * | 1991-02-27 | 1992-09-17 | Merrell Dow Pharmaceuticals Inc. | Nmda antagonists |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
US3996934A (en) * | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
US3742951A (en) * | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
US3921636A (en) * | 1973-01-15 | 1975-11-25 | Alza Corp | Novel drug delivery device |
US4031894A (en) * | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
GB8719102D0 (en) * | 1987-08-12 | 1987-09-16 | Merck Sharp & Dohme | Therapeutic agents |
CN1045596C (zh) * | 1993-11-29 | 1999-10-13 | 默里尔药物公司 | 杂环苯磺酰亚胺衍生物的药物用途,该类新化合物及其药物组合物 |
-
1994
- 1994-11-03 EP EP95901762A patent/EP0731791B1/en not_active Expired - Lifetime
- 1994-11-03 PT PT95901762T patent/PT731791E/pt unknown
- 1994-11-03 AT AT95901762T patent/ATE177083T1/de not_active IP Right Cessation
- 1994-11-03 CN CN94194304A patent/CN1044116C/zh not_active Expired - Fee Related
- 1994-11-03 AU AU10879/95A patent/AU683114B2/en not_active Ceased
- 1994-11-03 CA CA002175458A patent/CA2175458C/en not_active Expired - Fee Related
- 1994-11-03 DK DK95901762T patent/DK0731791T3/da active
- 1994-11-03 DE DE69416859T patent/DE69416859T2/de not_active Expired - Fee Related
- 1994-11-03 ES ES95901762T patent/ES2131297T3/es not_active Expired - Lifetime
- 1994-11-03 JP JP7515081A patent/JPH09506345A/ja active Pending
- 1994-11-03 US US08/649,663 patent/US5684017A/en not_active Expired - Fee Related
- 1994-11-03 KR KR1019960702804A patent/KR100340375B1/ko not_active IP Right Cessation
- 1994-11-03 HU HU9601435A patent/HU219565B/hu not_active IP Right Cessation
- 1994-11-03 NZ NZ276577A patent/NZ276577A/en unknown
- 1994-11-03 WO PCT/US1994/012658 patent/WO1995014669A1/en active IP Right Grant
- 1994-11-23 ZA ZA949303A patent/ZA949303B/xx unknown
- 1994-11-24 TW TW083111032A patent/TW279161B/zh active
- 1994-11-27 IL IL11177694A patent/IL111776A/xx active IP Right Grant
-
1996
- 1996-05-28 FI FI962235A patent/FI109901B/fi not_active IP Right Cessation
- 1996-05-28 NO NO962155A patent/NO306211B1/no unknown
-
1999
- 1999-03-30 GR GR990400918T patent/GR3029827T3/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992015565A1 (en) * | 1991-02-27 | 1992-09-17 | Merrell Dow Pharmaceuticals Inc. | Nmda antagonists |
Also Published As
Publication number | Publication date |
---|---|
PT731791E (pt) | 2000-11-30 |
IL111776A0 (en) | 1995-01-24 |
AU1087995A (en) | 1995-06-13 |
FI109901B (fi) | 2002-10-31 |
EP0731791B1 (en) | 1999-03-03 |
JPH09506345A (ja) | 1997-06-24 |
IL111776A (en) | 1999-06-20 |
ES2131297T3 (es) | 1999-07-16 |
TW279161B (hu) | 1996-06-21 |
HU219565B (hu) | 2001-05-28 |
FI962235A0 (fi) | 1996-05-28 |
HU9601435D0 (en) | 1996-07-29 |
NO306211B1 (no) | 1999-10-04 |
NZ276577A (en) | 1997-11-24 |
WO1995014669A1 (en) | 1995-06-01 |
CA2175458C (en) | 1999-03-02 |
GR3029827T3 (en) | 1999-06-30 |
NO962155D0 (no) | 1996-05-28 |
AU683114B2 (en) | 1997-10-30 |
ZA949303B (en) | 1995-08-07 |
US5684017A (en) | 1997-11-04 |
ATE177083T1 (de) | 1999-03-15 |
FI962235A (fi) | 1996-05-28 |
DK0731791T3 (da) | 1999-09-27 |
EP0731791A1 (en) | 1996-09-18 |
DE69416859D1 (de) | 1999-04-08 |
KR100340375B1 (ko) | 2002-11-13 |
KR960706476A (ko) | 1996-12-09 |
DE69416859T2 (de) | 1999-08-05 |
HUT76273A (en) | 1997-07-28 |
NO962155L (no) | 1996-05-28 |
CA2175458A1 (en) | 1995-06-01 |
CN1136311A (zh) | 1996-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1044116C (zh) | 用作il-1作用抑制剂的苯磺酰亚胺衍生物及其用途 | |
CN100339374C (zh) | 调节雌激素受体的化合物和方法 | |
CN1093759C (zh) | 蛋白激酶c抑制剂 | |
CN1056824C (zh) | 改进的环丙基乙炔合成 | |
CN1430603A (zh) | 新型双环化合物 | |
CN1135209A (zh) | 新的氨基甲酸苯基烷基氨基醇酯及其制备方法 | |
CN1708495A (zh) | 杂环化合物及以其为有效成分的抗肿瘤药 | |
CN1228775A (zh) | 作为时间生物学药物的苯并呋喃和苯并吡喃 | |
JP2013543504A (ja) | Ahr活性化因子としての1,2‐ジヒドロ‐4‐ヒドロキシ‐2‐オキソ‐キノリン‐3‐カルボキシアニリド | |
CN1138779C (zh) | 取代的三唑并-哒嗪衍生物及由其制得的药物组合物 | |
KR0178281B1 (ko) | 3-인돌릴 티오아세테이트 유도체 및 이를 함유하는 약제학적 조성물 | |
CN1450995A (zh) | 用于治疗青光眼的5-羟基吲唑衍生物 | |
CN1045596C (zh) | 杂环苯磺酰亚胺衍生物的药物用途,该类新化合物及其药物组合物 | |
CN1139572C (zh) | Nmda(n-甲基-d-天冬氨酸)拮抗剂 | |
CN87105612A (zh) | 嘧啶衍生物 | |
CN1352636A (zh) | 邻苯二酚腙衍生物及其制备方法以及含该衍生物的药物组合物 | |
CN1051302C (zh) | 3-(吲哚-3-基)丙烯酸衍生物及其用作nmda拮抗剂 | |
CN1058778A (zh) | 吲哚衍生物 | |
CN87103808A (zh) | 多巴胺-β-羟化酶抑制剂 | |
CN1161696A (zh) | 作为nmda拮抗剂的杂环取代的丙烯酸衍生物 | |
CN1671708A (zh) | 新的环烷二酮衍生物、它们的制备方法和它们的药物应用 | |
CN1134940A (zh) | 包含三氟甲基取代的2-氮杂二环辛烷的新的酰化假肽 | |
CN1054379C (zh) | 止痛化合物,它们的制备及其应用 | |
CN1049497A (zh) | 取代的苯甲酰脲化合物或它们的盐、它们的制备方法及含有该类物质的抗肿瘤组合物 | |
CN1110485C (zh) | 1-芳基磺酰基、芳基(硫代)羰基-哒嗪子基衍生物及其制法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |